Haleon PLC Sponsored ADR $HLN Shares Newly Acquired by Mondrian Investment Partners LTD

Mondrian Investment Partners LTD bought a new stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN) during the third quarter, Holdings Channel reports. The fund bought 17,637,434 shares of the company’s stock, valued at approximately $158,737,000. Haleon accounts for 3.4% of Mondrian Investment Partners LTD’s investment portfolio, making the stock its 11th largest holding.

Several other large investors have also modified their holdings of HLN. Arrowstreet Capital Limited Partnership lifted its position in shares of Haleon by 82.8% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 14,674,518 shares of the company’s stock worth $146,892,000 after purchasing an additional 6,647,329 shares during the period. Principal Financial Group Inc. boosted its stake in shares of Haleon by 27,393.7% during the first quarter. Principal Financial Group Inc. now owns 2,803,530 shares of the company’s stock valued at $28,063,000 after purchasing an additional 2,793,333 shares in the last quarter. Bank of America Corp DE increased its holdings in Haleon by 17.0% during the first quarter. Bank of America Corp DE now owns 10,934,228 shares of the company’s stock valued at $109,452,000 after buying an additional 1,586,230 shares during the period. JTC Employer Solutions Trustee Ltd increased its holdings in Haleon by 470.2% during the first quarter. JTC Employer Solutions Trustee Ltd now owns 1,610,721 shares of the company’s stock valued at $16,115,000 after buying an additional 1,328,217 shares during the period. Finally, Goodman Financial Corp purchased a new position in Haleon during the first quarter valued at approximately $11,488,000. Institutional investors own 6.67% of the company’s stock.

Haleon Stock Performance

Shares of Haleon stock opened at $10.29 on Friday. The company has a market capitalization of $45.30 billion, a PE ratio of 26.37, a P/E/G ratio of 2.32 and a beta of 0.14. The company has a 50-day simple moving average of $9.56 and a two-hundred day simple moving average of $9.51. Haleon PLC Sponsored ADR has a one year low of $8.65 and a one year high of $11.28. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.52 and a current ratio of 0.69.

Haleon Cuts Dividend

The company also recently disclosed a dividend, which was paid on Thursday, September 17th. Stockholders of record on Friday, August 14th were given a $0.0642 dividend. This represents a dividend yield of 132.0%. The ex-dividend date of this dividend was Friday, August 14th. This is a decrease from Haleon’s previous dividend of $0.1307. Haleon’s payout ratio is presently 30.77%.

Wall Street Analyst Weigh In

HLN has been the subject of a number of recent research reports. Zacks Research downgraded shares of Haleon from a “hold” rating to a “strong sell” rating in a research note on Thursday. Morgan Stanley reaffirmed an “overweight” rating on shares of Haleon in a research report on Thursday, August 6th. Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of Haleon in a research report on Tuesday, August 11th. Berenberg Bank reiterated a “buy” rating on shares of Haleon in a report on Wednesday, August 5th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Haleon in a research report on Wednesday, September 23rd. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Haleon presently has an average rating of “Moderate Buy” and an average target price of $4.90.

Haleon Profile

Haleon plc (NYSE: HLN) is a global consumer health company that develops, manufactures and markets over-the-counter medicines, oral health products, vitamins and supplements. Its portfolio is organized around categories including pain relief, respiratory health, digestive health, therapeutic oral care, everyday oral care, vitamins and minerals, and skin health.

Haleon’s well-known brands include Sensodyne, Polident, parodontax, Centrum, Advil, Voltaren, Panadol, Otrivin and Theraflu. The company’s products are sold through pharmacies, supermarkets, retailers and e-commerce channels, serving consumers in markets around the world.

Haleon was established as an independent consumer health business following its demerger from GSK in July 2022.